Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Safety and Tolerability Study of IMR-687 in Adults With Beta Thalassemia
2019-002989-12Phase 2Unknown
- Sponsor
- Imara Therapeutics
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tovinontrine in beta thalassemia (2 arms), sponsored by Imara Therapeutics. Primary endpoint: Primary: Safety and tolerability of IMR-687. Status: unknown.
02
Drugs
tovinontrine
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on 2019-002989-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002989-12.